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ABSTRACT
Management of spinal metastases is a complex process which includes services
ranging from neurological surgery to medical oncology to radiation oncology.
Neurosurgery hospitalists increasingly play a crucial role by coordinating diagnostic
and therapeutic strategies, tailoring them to each patient’s individual needs. In this
article, we review each step of the management of the spine mass from diagnosis to
treatment. An emphasis is placed on the diagnosis and management of metastatic
spinal cord compression. Finally, we review in detail the role of the neurosurgery
hospitalist in this process.

INTRODUCTION
Metastatic disease in patients with solid and hematological malignancies is an important adverse prognostic factor, as it is associated with significantly higher rates of
morbidity and mortality. Autopsy studies of patients with cancer reveal that up to 70%
had also developed metastases to bone.1,2,3 Greater than 80% of these bone metastases are attributable to three primary malignancies: breast, prostate, and lung (though
many others, including thyroid, renal, and colon cancer also frequently metastasize to
bone). 2,3 The spine is the most common site of osseous metastasis, and its increasingly
high prevalence on autopsy is in large part due to the improved overall survival of
patients living with cancer. 2,3
Physiologic factors contributing to the origin and severity of spinal metastases include
(a) Batson venous plexus, which is responsible for drainage of the abdominal and pelvic
organs, and (b) growth factors released from bone marrow stroma by tumor-mediated
structural degradation, which then induce growth and proliferation of the invading
tumor cells (in addition to osteoblastic and osteoclastic activity). 2,4,5 Bone metastases
are either sclerotic, lytic, or mixed, depending on the degree to which they stimulate
osteoblasts, osteoclasts, or both.5,6
The most dreaded complication of spinal cord metastasis is metastatic spinal cord
compression (MSCC), first described by William G. Spiller, MD in 1925.7 Approximately
5% of all patients with cancer develop MSCC, while as many as 20% of patients with
spinal metastases suffer MSCC4.8 Breast, lung, prostate, and renal cancer are responsible for the majority of MSCC.9,10 The thoracic spine (60%) is the most commonly
implicated region, followed by the lumbar spine (25%), and cervical spine (15%).4,9 When
MSCC occurs, the culprit lesion is located within the vertebral body itself in about 85%
of cases, whereas paravertebral spaces are the origin in 15% of cases.4 As with spinal
metastases in general, the overall incidence of MSCC has increased, which likely also
is due to the increasing longevity of patients with cancer.11

CLINICAL PRESENTATION
The most common symptom of spinal
metastases and MSCC is new or worsening back pain.4,9,10 Bone metastasis is
the most common cause of cancer-associated pain and represents multifactorial
pathophysiology, including osteolysis,
tumor-induced growth factor production, nerve infiltration, and periosteal
distension.4,6 The characteristics of this
pain typically are somatic, neuropathic,
or both. Somatic pain is localized and
worsened by movement or manipulation
of the affected region, while neuropathic
pain typically radiates, burns, and worsens
at night.4,6 In high risk patient populations,
sudden and severe worsening of pain
should raise suspicion for a pathological
fracture, which may result from either
osteolytic or osteoblastic lesions.4,5
Neurological injury in MSCC is due to
compression-mediated demyelination
and axonal damage, along with vascular
compromise leading to vasogenic
edema, ischemia, and ultimately infarction of the spinal cord4. The incidence of
focal extremity weakness due to MSCC
ranges from 35% to 75% and represents
the most common focal neurological
manifestation.4,12 It is often associated
with ambulatory dysfunction, though
the degree of impairment varies greatly.
Sensory deficits are less common, typically
preceded by pain and motor impairment,
progress distally to proximally, and may be
associated with more severe neurological
injury4, 12. Bowel and bladder dysfunction are grave features of MSCC and are
seen in 50-60% of cases.4 When present,
sphincter dysfunction (tested by digital
rectal examination and measurement of
urinary post-void residuals) represents a
poor prognostic indicator and reduces
the likelihood of complete functional
neurological recovery.4,13 While the characteristic syndrome of MSCC includes
the above manifestations, many patients
present with more general signs and
symptoms, such as nonspecific pain and
ambulatory dysfunction.4,12
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CLINICAL PRESENTATION
AND EVALUATION OF
METASTATIC SPINAL CORD
COMPRESSION

Experts recommend MRI evaluation of the
entire spine, as up to 30% of patients with
MSCC have more than one metastatic
lesion in the spine.15,20

abnormalities, CT is far inferior to MRI
when it comes to delineation of soft
tissues and the diagnosis of spinal cord
compression.

Metastatic spinal cord compression is a
medical and surgical emergency requiring
immediate evaluation and intervention to
prevent paralysis and other irreversible
neurological injury.4,14 It is paramount
that clinicians maintain a high index
of suspicion and promptly evaluate
symptoms that raise the possibility of
spinal metastatic disease or MSCC,
particularly in patients with an established diagnosis of malignancy.6,15 Poor
prognostic factors include prolonged
duration of neurological deficit, severe
neurological compromise, prior radiation treatment of metastatic lesions,
and metastases located in the thoracic
spine (although there are only few and
low-quality studies to establish these
prognostic features). 16 Patients who
are unable to lift their legs against
gravity and those who have been nonambulatory for greater than 48 hours
are at greatest risk of poor functional
recovery. 16

Fortunately, data suggest that patients
with MSCC today are more likely to experience significant functional recovery. A
study in 2010 showed that 62% of patients
with MSCC were ambulatory at the time of
their diagnosis and intervention, whereas
only approximately one-third of patients
in the 1990s remained ambulatory by the
time of intervention.14,21,22 In addition to
early diagnosis, multiple studies have
demonstrated that early surgical intervention (in appropriate candidates) plus
radiation therapy improves outcomes in
comparison to radiation therapy alone. 2,
6,14,17,9,10,12,23,24,25
. Historically, laminectomy alone was the standard method of
surgical intervention, but more recent
studies and surgical advances support
decompression and fusion for stabilization over decompression alone. 2,16,17,21, 23

Standardized use of MRI in the evaluation of spinal metastatic disease has
greatly impacted the management and
outcome expectations for patients. In
addition to its superior visualization of the
spinal cord and surrounding soft tissue,
MRI remains the only modality capable
of evaluating the bone marrow and its
constituent elements with high resolution.
T1-weighted MR scans are particularly
useful for the evaluation of bone marrow
due to the hyperintense signal generated
by its high fat content, which enables
detection of focal hypointense lesions
relative to the surrounding normal tissue.
In contrast, T2-weighted MR images
show metastatic lesions as hyperintense
compared to bone marrow, due to their
relatively high water content. The addition of intravenous contrast further aids
detection of lesions in the epidural space,
as well as MSCC. A limitation of MRI,
however, is its inability to differentiate
conclusively between changes resulting
from tumor versus those from surgery.

Ambulatory status at the time of diagnosis
carries the greatest power of prognostication, as multiple studies demonstrate
improved post-treatment outcomes and
functional capacity for patients who
were able to ambulate at the time of
intervention.10,12,17 There is insufficient
standardization in the assessment of
pre-treatment functional capacity and
inadequate tools for quantifying the
post-treatment prognosis, but experts
agree that pre-treatment ambulation
is strongly linked to better outcomes
and reduced rates of morbidity and
mortality.16-19
Given the preceding prognostic considerations, early detection, diagnosis, and
intervention in cases of MSCC is crucial
to improving patients’ outcomes. 14,18
The gold-standard imaging modality
to diagnose MSCC is magnetic resonance imaging (MRI), which confers a
high diagnostic sensitivity (93%) and
specificity (97%). 2,4,8 MRI offers detailed
visualization of the spinal cord and its
surrounding structures and is useful not
only for surgical planning, but also for
identifying targets in cases when emergent radiation treatment is necessary,1, 2,4,8
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Overall median survival rates for patients
with MSCC range between 6 to 9
months.18,19,21,25,26 In addition to patients’
functional and ambulatory condition,
survival rates are greatly influenced by
the type and features of the primary
malignancy. 25 Lung cancer and cancer
of unknown primary causing MSCC bear
the worst prognoses, while prostate and
myeloma are associated with more favorable outcomes.18,19,25,26

NEUROIMAGING IN THE
DIAGNOSIS OF SPINAL
METASTASES
Historically, plain film radiographs were
the first imaging test used for the diagnosis of spinal metastatic disease. With
the advent of more sophisticated imaging
modalities, however, radiographs are no
longer routinely utilized for this purpose.
Radiographs require a minimum mass
diameter of 1 cm and a bone density
of 50% or greater to achieve adequate
visualization, resulting in a very high rate
of false negative tests. The development
of computed tomography (CT) scans
presented a significant advancement, as
they can detect bony metastatic lesions
up to 6 months before they are reliably
identified on radiograph. Nevertheless,
though excellent for detecting bony

Biopsy is the gold standard test to determine the primary origin of any metastatic
lesion. Neuroimaging can play a role in
identifying the tissue of origin during the
early stages of a metastatic evaluation,
as many malignancies cause either lytic
(osteoclast-predominant) or sclerotic
(osteoblast-predominant) bony lesions
(though some are characterized by
mixed features). Primary cancers of the
lung, breast, thyroid, adrenal glands, and
melanoma (among others) cause lytic
bony metastases. In contrast, prostate,
bladder, and nasopharyngeal cancers
cause sclerotic metastases. Cancers of
ovarian, cervical, testicular, and occasionally lung etiology may cause mixed—lytic
and sclerotic—patterns. Both lytic and
sclerotic lesions involving the posterior
cortex may cause destruction of the
cortex and pedicles. An important sign
of diffuse bone marrow infiltration is a
hyperintense appearance of the vertebral discs in comparison to bone on a
T1-weighted MRI. A systematic grading
of spinal cord compression proposed by
Bilsky and colleagues is commonly used
to stratify the severity of MSCC. 27

Spinal Metastasis

Other imaging modalities that have proven
useful in screening for bone metastases
are bone scintigraphy and single-photonemission computed tomography (SPECT).
These are nuclear medicine scans that
operate by injection of a radioactive
tracer that accumulates in newly formed
bone at the site of a metastatic lesion.
Neoplastic lesions appear “hot” (indicative of increased bone turnover, including
degradation and formation), but this effect
may not be seen in cases where the cancer
has caused excessive tissue destruction
and consequently impaired blood flow
to the site. One of the best modalities for
visualization of bone marrow involvement
is the [18F] fluoro-2-deoxy-d-glucose
positron emission tomography (FDG-PET)
scan, which measures glucose metabolism and thus preferentially highlights areas
of increased bone cell turnover. This is
particularly useful for when evaluating for
multiple myeloma.28

MANAGEMENT OF SPINAL
METASTASTIC DISEASE
General considerations of treatment
Metastatic malignancy generally is an
incurable disease. Whether and how
to pursue treatment requires careful
consideration of several patient and
disease-specific determinants. Physicians should proactively seek to
understand each patient’s perceptions,
expectations, and preferences. In their
2017 report, the International Spine
Oncology Consortium proposed a
number of factors to consider prior to
initiating treatment, beginning with a
thorough assessment of the patient’s
baseline functional status. 29 The
Karnofsky performance scale and the
Eastern Cooperative Oncology Group
(ECOG) scale are commonly used in
general oncology as functional performance evaluators. Patients with ‘poor
functional status’ are generally defined
as those with a Karnofsky performance
score of less than 40.
The overall burden of disease also
plays a significant prognostic role, even
following treatment of spinal lesions.
Extensive extra-spinal metastatic disease
denotes a poor prognosis for survival
after spinal radiation. Some tumor types
(for example, hormone-sensitive breast

cancer and lung cancer with targetsensitive genomic alterations) have more
favorable prognostic profiles, and this
must also be factored into spine-specific
treatment paradigms. Hematological
cancers affecting the spine generally
have well-established systemic treatment protocols that may be favored
over surgery or local radiation, at times
even when cord compression is present.
Similarly, tumor histology is important
in predicting whether conventional
external beam radiation therapy (cEBRT)
can achieve durable local response, as
some histologies are more radiosensitive
than others. Finally, mechanical stability
of the spine, commonly assessed by the
Spine Instability Neoplastic Score (SINS),
will greatly influence treatment options
as the primary goal in mechanically
unstable spines is to restore structural
stability.30 SINS incorporates both clinical
and radiological features and scores
range from 0 to 18, with higher numbers
signifying a higher degree of instability.

Radiation therapy
The two most common forms of radiation
therapy for spinal metastases are external
beam radiation therapy (EBRT) and stereotactic body radiation therapy (SBRT). The
former is most frequently employed, while
the latter often is reserved for specifically
indicated circumstances. The primary goal
of EBRT is palliation and it is the preferred
treatment for radiosensitive tumors (e.g.
lymphoma, myeloma, germ cell tumors).
Practice guidelines, informed by multiple
randomized controlled trials, favor shorter
fractionated regimens of EBRT over more
protracted ones, as they have been shown
to be noninferior in their primary outcome
(pain control) and associated with fewer
acute post-treatment adverse effects.31,32
SBRT utilizes confocal beams of radiation to precisely target a specific site,
while avoiding collateral radiation
damage to important adjacent structures. It is particularly useful for the
treatment of relatively radioresistant
tumors like sarcoma, melanoma, and
renal cell carcinoma. It is also used
in patients who have persistent pain
despite treatment with EBRT. 33 SBRT is
associated with a higher risk of vertebral
compression fractures. It is worth noting,
however, that SBRT and EBRT have not

been compared directly in prospective
randomized controlled trials.

Surgery
The two main indications for surgical
consultation in spinal metastatic disease
are spinal instability and MSCC. Surgical
consultation (by a neurosurgeon or
specialized orthopedic spine surgeon)
generally is recommended for any patient
with a SINS greater than 72. 34,35 MSCC
is a medical emergency and surgery
is a critical component in the care of
patients with MSCC. Surgical intervention typically is pursued in conjunction
with medical and radiation therapy, as
multiple clinical trials involving MSCC
have demonstrated significantly better
outcomes in patients treated with
surgery plus radiation in comparison to
radiation therapy alone.36 These findings
have led to expansion of the surgical
role in the management of MSCC and
advancements in surgical technique. A
trial by Patchell et al. found that more
patients in the surgical group (84%) were
able to ambulate after treatment versus
the radiation monotherapy group (57%),
and they remained ambulatory for a
longer duration (median 122 days versus
13 days). 37 Minimally invasive techniques
like cement augmentation of vertebral
bodies are increasingly used and have
proven effective in the management of
certain disease presentations, such as
pathological fractures. 2,38
Another benefit of surgical intervention
is to facilitate safe delivery of postoperative radiation therapy. Spine separation
surgery is one such procedure which
creates a gap access to the tumor,
allowing radiation to be administered,
while sparing the spinal cord and the
cauda equina from direct exposure and
potential radiation damage. 39-41

Medical management
The aspect of medical management that
is most directly relevant to the hospitalist
or general internist is analgesia, since
pain is the most common symptom
in spine metastasis. Mild bone pain is
usually managed well with scheduled
acetaminophen, with or without a
nonsteroidal anti-inflammatory drugs
(NSAID). As pain becomes more severe,
the addition of an oral opioid agent

JHN JOURNAL

17

may be necessary. In the hospital, this
approach can be combined with intravenous opioids for breakthrough pain,
titrated to therapeutic efficacy while at
the same time avoiding neurological and
respiratory side effects. Glucocorticoids
are frequently used to improve outcomes
when there is MSCC, but they are also a
useful adjunct for analgesia.42
Osteoclast inhibitors reverse or delay
the progression of bone metastases and
reduce the likelihood of skeletal-related
events (SREs). Denosumab and zoledronic acid (a bisphosphonate) are the
most frequently utilized agents.43 Denosumab has been shown to have a benefit
over zoledronic acid in reducing overall
bone tumor burden, but comes with a
significant additional cost, resulting in
the more common use of the latter.43,44
The well-known adverse effects of these
agents include jaw necrosis, hypocalcemia, increased risk of atrial fibrillation
and stroke (bisphosphonates), and a
higher risk of infection (denosumab).
Depending on the primary tumor identified on biopsy, systemic chemotherapy
and more recently developed targeted
therapy or immunotherapy may play
a role in controlling systemic disease
burden. 29,45 Systemic chemotherapy
regimens generally come with a significantly increased risk of toxicity, and the
treating hospitalist should be cognizant
of possible adverse effects during the
course of therapy.

ROLE OF THE HOSPITALIST
PHYSICIAN IN THE
MANAGEMENT OF PATIENTS
WITH SPINAL MASS
The medical complexity of hospitalized patients has increased substantially
over time, making multidisciplinary care
increasingly necessary and common. In
addition, patients with disseminated cancer
are likely to be older, and are thus more
likely to have multiple medical comorbidities that complicate their pre- and
postoperative care. Much like the primary
care physician in the outpatient setting,
the hospitalist physician today serves an
important role in coordinating treatment
plans among multiple care teams and is
vital to managing medical comorbidities.
Hospitalists are often called upon to
evaluate patients for their overall risk
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for surgery, therefore today’s hospitalist
needs a deep understanding of perioperative medicine, and must be well
versed in the utilization of the multiple
risk stratification tools. For a risk assessment of major adverse cardiac and
cerebrovascular events (MACCE) the
hospitalist needs to be familiar with the
Gupta Score and the Revised Cardiac
Risk Index (RCRI).46,47 They also need to
understand the current AHA/ACC guidelines for perioperative assessment,48 as
well as ASA classification.49 Although
the risk of MACCE is a central part of
preoperative assessment, there are other
tools to aid with risk stratification, such
as the risk of postoperative respiratory
failure estimated by ARISCAT.50 The risk
of postoperative venous thromboembolism is defined using the Caprini score.51
Understanding which patients can
proceed to surgery without delay and
which patients need further testing for
enhanced risk stratification is an integral
skill for the current hospitalist.
In the postoperative period the hospitalist continues to play an important
role, as they are often consulted to
manage postoperative sequelae. In the
postoperative period the hospitalist may
be called upon to manage metabolic
complications and electrolyte disturbances, or to manage hyperglycemia in
steroid-treated patients and diabetics.
Prevention, early detection and treatment
of postoperative venous thromboembolic disease (VTE) are also critical
management skills for the hospitalist, as
are the detection and management of
postoperative infections. Additionally,
the hospitalist must feel comfortable
managing acute postoperative pain,
and working collaboratively with dedicated pain medicine services. Lastly, the
hospitalist must frequently assess goals
of care, and involve palliative care when
indicated, after careful consultation with
their surgical colleagues.

REFERENCES:
1. Tseng C-L, Eppinga W, Charest-Morin R,
Soliman H, Myrehaug S, Maralani PJ, et al.
Spine stereotactic body radiotherapy: indications, outcomes, and points of caution.
Global Spine J 2017; 7: 179–97.
2. Mossa-Basha M, Gerszten PC, Myrehaug
S, Mayr NA, Yuh WT, Jabehdar Maralani P,
Sahgal A, Lo SS. Spinal metastasis: diagnosis,
management and follow-up. Br J Radiol.
2019 Nov;92(1103):20190211.

3. Maccauro G, Spinelli MS, Mauro S, Perisano
C, Graci C, Rosa MA. Physiopathology
of spine metastasis. Int J Surg Oncol.
2011;2011:107969.
4. Cole JS1, Patchell RA. Metastatic epidural
spinal cord compression. Lancet Neurol.
2008 May;7(5):459-66. doi: 10.1016/S14744422(08)70089-9.
5. Clézardin P. Pathophysiology of bone
metastases from solid malignancies. Joint
Bone Spine. 2017 Dec; 84(6): 677-684. doi:
10.1016/j.jbspin.2017.05.006. Epub 2017 May 9.
6. Macedo, Ladeira, Pinho, Saraiva, Bonito,
Pinto, and Goncalves. Bone Metastases: An
Overview. Oncol Rev. 2017 Mar 3; 11(1): 321.
7. Spiller, WG. Rapidly progressive paralysis
associated with sarcoma. Arch NeurPsych.
1925;13(4): 471-478.
8. Sutcliffe P, Connock M, Shyangdan D, Court
R, Kandala NB, Clarke A. A systematic review
of evidence on malignant spinal metastases:
natural history and technologies for identifying patients at high risk of vertebral fracture
and spinal cord compression. Health Technol
Assess. 2013 Sep;17(42):1-274.
9. Gilbert RW, Kim JH, Posner JB. Epidural spinal
cord compression from metastatic tumor:
diagnosis and treatment. Ann Neurol, 3
(1978), pp. 40-51.
10. F Bach, BH Larsen, K Rohde, et al. Metastatic
spinal cord compression, occurrence, symptoms, clinical presentations and prognosis in
398 patients with spinal cord compression.
Acta Neurochir, 107 (1990), pp. 37-43.
11. Karhade AV, Shin JH, Schwab JH. Prognostic
models for spinal metastatic disease: evolution of methodologies, limitations, and
future opportunities. Ann Transl Med. 2019
May;7(10):219.
12. Boussios S, Cooke D, Hayward C, Kanellos FS,
Tsiouris AK, Chatziantoniou AA, ZakynthinakisKyriakou N, Karathanasi A. Metastatic Spinal
Cord Compression: Unraveling the Diagnostic
and Therapeutic Challenges. Anticancer Res.
2018 Sep;38(9):4987-4997.
13. S Helweg-Larsen, PS Sorenson. Symptoms
and signs in metastatic spinal cord compression: a study of progression from first symptoms until diagnosis in 153 patients. Eur J
Cancer, 30A (1994), pp. 396-398.
14. Husband DJ. Malignant spinal cord compression: prospective study of delays in referral and
treatment. BMJ. 1998 Jul 4;317(7150):18-21.
15. Lawton AJ, Lee KA, Cheville AL, Ferrone ML,
Rades D, Balboni TA, Abrahm JL. Assessment
and Management of Patients With Metastatic
Spinal Cord Compression: A Multidisciplinary
Review. J Clin Oncol. 2019 Jan 1;37(1):61-71.
16. Laufer I, Zuckerman SL, Bird JE, Bilsky MH,
Lazáry Á, Quraishi NA, Fehlings MG, Sciubba
DM, Shin JH, Mesfin A, Sahgal A, Fisher CG.
Predicting Neurologic Recovery after Surgery
in Patients with Deficits Secondary to MESCC:
Systematic Review. Spine (Phila Pa 1976).
2016 Oct 15;41 Suppl 20:S224-S230.

Spinal Metastasis

17. Sørensen S1, Børgesen SE, Rohde K,
Rasmusson B, Bach F, Bøge-Rasmussen T,
Stjernholm P, Larsen BH, Agerlin N, Gjerris
F, et al. Metastatic epidural spinal cord
compression. Results of treatment and
survival. Cancer. 1990 April 1; 65(7): 1502-8.
18. Maranzano E, Latini P, Beneventi S, Marafioti
L, Piro F, Perrucci E, Lupattelli M. Comparison
of two different radiotherapy schedules for
spinal cord compression in prostate cancer.
Tumori. 1998 Jul-Aug;84(4):472-7.
19. da Silva GT, Bergmann A, Santos Thuler LC.
Prognostic factors in patients with metastatic
spinal cord compression secondary to lung
cancer: a systematic review of the literature.
Eur Spine J. 2015 Oct;24(10):2107-13.
20. Schiff D, O'Neill BP, Wang CH, O'Fallon JR.
Neuroimaging and treatment implications of
patients with multiple epidural spinal metastases. Cancer. 1998 Oct 15;83(8):1593-601.
21. Rades D, Huttenlocher S, Dunst J, Bajrovic
A, Karstens JH, Rudat V, Schild SE. Matched
pair analysis comparing surgery followed
by radiotherapy and radiotherapy alone for
metastatic spinal cord compression. J Clin
Oncol. 2010 Aug 1;28(22):3597-604.
22. Findlay GF. Adverse effects of the management of malignant spinal cord compression. J Neurol Neurosurg Psychiatry. 1984
Aug;47(8):761-8.
23. Fehlings MG, Nater A, Tetreault L, Kopjar B,
Arnold P, Dekutoski M, Finkelstein J, Fisher C,
France J, Gokaslan Z, Massicotte E, Rhines
L, Rose P, Sahgal A, Schuster J, Vaccaro A.
Survival and Clinical Outcomes in Surgically
Treated Patients With Metastatic Epidural
Spinal Cord Compression: Results of the
Prospective Multicenter AOSpine Study. J Clin
Oncol. 2016 Jan 20;34(3):268-76.
24. Di Martino A, Caldaria A, De Vivo V, Denaro V.
Metastatic epidural spinal cord compression.
Expert Rev Anticancer Ther. 2016 Nov; 16(11):
1189-1198. doi: 10.1080/14737140.2016.1240038.
Epub 2016 Oct 12.
25. Wänman J, Grabowski P, Nyström H,
Gustafsson P, Bergh A, Widmark A, Crnalic
S. Metastatic spinal cord compression
as the first sign of malignancy. Acta
Orthop. 2017 Aug; 88(4): 457-462. doi:
10.1080/17453674.2017.1319179. Epub 2017
May 11.
26. Chen TC. Prostate cancer and spinal cord
compression. Oncology (Williston Park). 2001
Jul;15(7):841-55.
27. Bilsky MH, Laufer I, Fourney DR, Groff M,
Schmidt MH, Varga PP, Vrionis FD, Yamada Y,
Gerszten PC, Kuklo TR. Reliability analysis of
the epidural spinal cord compression scale. J
Neurosurg Spine. 2010 Sep;13(3):324-8.
28. Hur J, Yoon CS, Ryu YH, Yun MJ, Suh JS.
Comparative study of fluorodeoxyglucose
positron emission tomography and magnetic
resonance imaging for the detection of spinal
bone marrow infiltration in untreated patients
with multiple myeloma. Acta Radiol. 2008
May;49(4):427-35.

29. Spratt DE, Beeler WH, de Moraes FY, Rhines
LD, Gemmete JJ, Chaudhary N, Shultz DB,
Smith SR, Berlin A, Dahele M, Slotman BJ,
Younge KC, Bilsky M, Park P, Szerlip NJ.
An integrated multidisciplinary algorithm
for the management of spinal metastases: an International Spine Oncology
Consortium report. Lancet Oncol. 2017
Dec;18(12):e720-e730.
30. Pennington Z, Ahmed AK, Cottrill E,
Westbroek EM, Goodwin ML, Sciubba DM.
Intra- and interobserver reliability of the
Spinal Instability Neoplastic Score system for
instability in spine metastases: a systematic
review and meta-analysis. Ann Transl Med.
2019 May;7(10):218.
31. Hartsell WF, Scott CB, Bruner DW, Scarantino
CW, Ivker RA, Roach M 3rd, Suh JH,
Demas WF, Movsas B, Petersen IA, Konski
AA, Cleeland CS, Janjan NA, DeSilvio M.
Randomized trial of short- versus longcourse radiotherapy for palliation of painful
bone metastases. J Natl Cancer Inst. 2005
Jun 1;97(11):798-804.
32. Lutz S, Berk L, Chang E, Chow E, Hahn C,
Hoskin P, Howell D, Konski A, Kachnic L,
Lo S, Sahgal A, Silverman L, von Gunten C,
Mendel E, Vassil A, Bruner DW, Hartsell W;
American Society for Radiation Oncology
(ASTRO). Palliative radiotherapy for bone
metastases: an ASTRO evidence-based
guideline. Int J Radiat Oncol Biol Phys. 2011
Mar 15;79(4):965-76.
33. Lutz S, Balboni T, Jones J, Lo S, Petit J, Rich
SE, Wong R, Hahn C8. Palliative radiation
therapy for bone metastases: Update of an
ASTRO Evidence-Based Guideline. Pract
Radiat Oncol. 2017 Jan – Feb;7(1):4-12. doi:
10.1016/j.prro.2016.08.001. Epub 2016 Aug 5.
34. Fisher CG, DiPaola CP, Ryken TC, Bilsky MH,
Shaffrey CI, Berven SH, Harrop JS, Fehlings
MG, Boriani S, Chou D, Schmidt MH, Polly
DW, Biagini R, Burch S, Dekutoski MB, Ganju
A, Gerszten PC, Gokaslan ZL, Groff MW,
Liebsch NJ, Mendel E, Okuno SH, Patel S,
Rhines LD, Rose PS, Sciubba DM, Sundaresan
N, Tomita K, Varga PP, Vialle LR, Vrionis FD,
Yamada Y, Fourney DR. A novel classification system for spinal instability in neoplastic
disease: an evidence-based approach and
expert consensus from the Spine Oncology
Study Group. Spine (Phila Pa 1976). 2010 Oct
15;35(22):E1221-9.
35. Fourney DR, Frangou EM, Ryken TC, Dipaola
CP, Shaffrey CI, Berven SH, Bilsky MH, Harrop
JS, Fehlings MG, Boriani S, Chou D, Schmidt
MH, Polly DW, Biagini R, Burch S, Dekutoski
MB, Ganju A, Gerszten PC, Gokaslan ZL, Groff
MW, Liebsch NJ, Mendel E, Okuno SH, Patel S,
Rhines LD, Rose PS, Sciubba DM, Sundaresan
N, Tomita K, Varga PP, Vialle LR, Vrionis
FD, Yamada Y, Fisher CG. Spinal instability
neoplastic score: an analysis of reliability and
validity from the spine oncology study group.
J Clin Oncol. 2011 Aug 1;29(22):3072-7.
36. Yahanda AT, Buchowski JM, and Wegner AM.
Treatment, complications, and outcomes of
metastatic disease of the spine: from Patchell to
PROMIS. Ann Transl Med. 2019 May; 7(10): 216.

37. Patchell RA, Tibbs PA, Regine WF, Payne R,
Saris S, Kryscio RJ, Mohiuddin M, Young B.
Direct decompressive surgical resection in the
treatment of spinal cord compression caused
by metastatic cancer: a randomised trial.
Lancet. 2005 Aug 20-26;366(9486):643-8.
38. Mendel E, Bourekas E, Gerszten P, Golan JD.
Percutaneous techniques in the treatment of
spine tumors. Spine 2009; 34: S93–S10.
39. Ejima Y, Matsuo Y, Sasaki R. The current status
and future of radiotherapy for spinal bone
metastases. J Orthop Sci 2015;20:585-92
40. Laufer I, Rubin DG, Lis E, et al. The NOMS
Framework: Approach to the Treatment
of Spinal Metastatic Tumors. Oncologist
2013;18:744-51.
41. Barzilai O, Laufer I, Yamada Y, et al. Integrating
evidence-based medicine for treatment of
spinal metastases into a decision framework: Neurologic, oncologic, mechanicals
stability, and systemic disease. J Clin Oncol
2017;35:2419-27.
42. Mei N and Sharan AD. Perioperative optimization of pain control in patients undergoing
spinal surgery using multimodal anesthesia.
In Medical management of neurosurgical
patients, Oxford University Press, 2019. Edited
by R. Daniel and C.M. Harrop. Pages 213-232.
43. Battafarano G, Rossi M, Marampon F, and Del
Fattore A.. Cellular and Molecular Mediators
of Bone Metastatic Lesions. Int J Mol Sci.
2018 Jun; 19(6): 1709.
44. Shapiro CL, Moriarty JP, Dusetzina S,
Himelstein AL, Foster JC, Grubbs SS, Novotny
PJ, Borah BJ. Cost-Effectiveness Analysis of
Monthly Zoledronic Acid, Zoledronic Acid
Every 3 Months, and Monthly Denosumab
in Women With Breast Cancer and Skeletal
Metastases: CALGB 70604 (Alliance). J Clin
Oncol. 2017 Dec 10;35(35):3949-3955. doi:
10.1200/JCO.2017.73.7437. Epub 2017 Oct 12.
45. Barzilai O, Fisher CG, Bilsky MH. State of the
Art Treatment of Spinal Metastatic Disease.
Neurosurgery. 2018 Jun 1;82(6):757-769.
46. Gupta PK, Gupta H, Sundaram A, et al.
Development and Validation of a Risk
Calculator for Prediction of Cardiac Risk After
Surgery. 2011.
47. Lee TH, Marcantonio ER, Mangione CM, et
al. Derivation and Prospective Validation of a
Simple Index for Prediction of Cardiac Risk of
Major Noncardiac Surgery. 1999.
48. Fleisher LA, Fleischmann KE, Auerbach AD, et
al. 2014 ACC/AHA Guideline on Perioperative
Cardiovascular Evaluation and Management
of Patients Undergoing Noncardiac Surgery:
Executive Summary. 2014.
49. Doyle DJ, Garmon EH. American Society
of Anesthesiologists Classification (ASA
Class). 2019.
50. Canet J, Gallart L, et al. Prediction of
Postoperative Pulmonary Complications
in a Population-based Surgical Cohort.
Anesthesiology: The Journal of the
American Society of Anesthesiologists.
2020;113(6):1338-1350.
51. JA C. Thrombosis Risk Assessment as a Guide
to Quality Patient Care. Disease-a-month:
DM. 2005;51(2-3).

JHN JOURNAL

19

